Acute Lymphoblastic Leukemia (ALL)
Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With CancerOctober 11, 2016
Children with cancer are at risk for developing behavioral problems after diagnosis.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.
Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.
Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.
Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic LeukemiaMay 20, 2016
Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.
[Clinical Oncology in Adolescents and Young Adults] This research reviews the outcomes with chemotherapy alone and with hematopoietic stem cell transplantation in acute lymphoblastic leukemia, and examines the challenges faced in determining the best therapy for the adolescents and young adult patient population.
Anxiety and Depressive Symptoms Are Increased in Pediatric Survivors of Acute Lymphoblastic LeukemiaApril 04, 2016
Emotional distress during and after undergoing chemotherapy for ALL affects a significant percentage of children with the disease.
A subtype-specific weakness of T-cell acute lymphoblastic leukemia (T-ALL) could enable improved treatment, according to results from a a recent study using a mouse model.
Study Findings Show Possible Association Between PreLabor Cesarean Delivery and Risk for ALL in Young ChildrenMarch 16, 2016
The finding that prelabor cesarean delivery may have a correlation with acute lymphoblastic leukemia (ALL) may offer new targets for research into preventing cancer.
Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.
Pediatric survivors of ALL treated only with chemotherapy remain at an increased risk for attention problems 2 years after treatment cessation.
Abnormal breakage and chromosomal rearrangement in white blood cells result in a particularly aggressive Philadelphia chromosome-like ALL, according to a new study.
Significant bone loss in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) occurs during the first month of treatment.
A new study examined levels of procedure-related anxiety in children with standard-risk acute lymphoblastic leukemia (ALL).
Association Is Found Between Bone Complications in Young Pediatric Patients With Leukemia and Gene VariationsDecember 22, 2015
Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL).
Continuous antibiotic treatment can reduce infections in young patients with acute lymphoblastic leukemia (ALL).
Non-Hispanic children undergoing treatment for newly diagnosed acute lymphoblastic leukemia reported higher rates of fractures and opportunistic infections, according to new study data.
A new randomized study has evaluated the addition of rituximab to the pediatric-inspired GRAALL protocol for adults with acute lymphoblastic leukemia.
Treatment with high-dose methotrexate was linked to significantly higher rates of disease-free survival in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL), according to results from a recent phase 3 trial.
Subjective over-reporting of 6-mercaptopurine (6MP) intake during maintenance therapy for childhood acute lymphoblastic leukemia is common, according to a new cohort study.
Inotuzumab ozogamicin combined with low-intensity mini-hyper-CVD chemotherapy has demonstrated encouraging results in older patients with acute lymphoblastic leukemia, according to data from an ongoing study.
Inherited Gene Variation Linked to an Increased Risk of Pediatric Acute Lymphoblastic Leukemia (ALL)November 11, 2015
Researchers studying two generations of a family affected by pediatric ALL identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease.
An international team has decoded the molecular characteristics of acute lymphoblastic leukemia (ALL), a cancer with some incurable subtypes.
A recently developed drug holds great promise for some children with acute lymphoblastic leukemia (ALL).
A mutation of the gene ETV6 has been pinpointed as the heritable, genetic cause of acute lymphoblastic leukemia (ALL), according to a study.
Current research indicates that a rare but aggressive subtype of pediatric acute lymphoblastic leukemia (ALL) has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene.
Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.
Breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|